Sandra Rebelo1, Marta Drummond, José Agostinho Marques. 1. Department of Experimental Biology, Faculdade de Medicina do Porto, Universidade do Porto, Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal, srebelo1@gmail.com.
Abstract
PURPOSE: This study aimed to explore the impact of an 8-year therapy with autoadjusting positive airway pressure (APAP) on fasting lipid level in a sample of Portuguese moderate/severe obstructive sleep apnea (OSA) patients. Besides contributing to the comprehension of the complex relationship between dyslipidemia and OSA, it provided new data regarding the effectiveness of a long term APAP treatment. METHODS: Thirty-nine male patients with moderate to severe OSA were included in the study. APAP was prescribed to all patients. Fifteen patients were under lipid-lowering medication throughout the study, and another 15 patients never used lipid-lowering medication at any time during the study. Fasting morning venous blood samples were collected at three time points (baseline 6 months and 8 years) and lipids were estimated. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) 21.0 software. RESULTS: After 8 years of APAP treatment, patients presented a similar body mass index but a significantly less severe daytime sleepiness. Patients on lipid-lowering medication exhibited a higher reduction in total cholesterol than those naïf from that medication, but the reduction was not statistically significant after adjusting for medication and APAP adherence. CONCLUSIONS: Long-term APAP treatment improves OSA but does not seem to contribute to changes in fasting lipids.
PURPOSE: This study aimed to explore the impact of an 8-year therapy with autoadjusting positive airway pressure (APAP) on fasting lipid level in a sample of Portuguese moderate/severe obstructive sleep apnea (OSA) patients. Besides contributing to the comprehension of the complex relationship between dyslipidemia and OSA, it provided new data regarding the effectiveness of a long term APAP treatment. METHODS: Thirty-nine male patients with moderate to severe OSA were included in the study. APAP was prescribed to all patients. Fifteen patients were under lipid-lowering medication throughout the study, and another 15 patients never used lipid-lowering medication at any time during the study. Fasting morning venous blood samples were collected at three time points (baseline 6 months and 8 years) and lipids were estimated. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) 21.0 software. RESULTS: After 8 years of APAP treatment, patients presented a similar body mass index but a significantly less severe daytime sleepiness. Patients on lipid-lowering medication exhibited a higher reduction in total cholesterol than those naïf from that medication, but the reduction was not statistically significant after adjusting for medication and APAP adherence. CONCLUSIONS: Long-term APAP treatment improves OSA but does not seem to contribute to changes in fasting lipids.
Authors: Susan Redline; Gayane Yenokyan; Daniel J Gottlieb; Eyal Shahar; George T O'Connor; Helaine E Resnick; Marie Diener-West; Mark H Sanders; Philip A Wolf; Estella M Geraghty; Tauqeer Ali; Michael Lebowitz; Naresh M Punjabi Journal: Am J Respir Crit Care Med Date: 2010-03-25 Impact factor: 21.405
Authors: Stuart F Quan; Rohit Budhiraja; Denise P Clarke; James L Goodwin; Daniel J Gottlieb; Deborah A Nichols; Richard D Simon; Terry W Smith; James K Walsh; Clete A Kushida Journal: J Clin Sleep Med Date: 2013-10-15 Impact factor: 4.062
Authors: B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab Journal: J Clin Invest Date: 1995-12 Impact factor: 14.808
Authors: Craig L Phillips; Brendon J Yee; Nathaniel S Marshall; Peter Y Liu; David R Sullivan; Ronald R Grunstein Journal: Am J Respir Crit Care Med Date: 2011-04-28 Impact factor: 21.405
Authors: Patricia K Nguyen; Chandra K Katikireddy; Michael V McConnell; Clete Kushida; Phillip C Yang Journal: J Cardiovasc Magn Reson Date: 2010-09-03 Impact factor: 5.364